A Multimodal Therapeutic Strategy for Inflammatory Bowel Disease Using MicroRNA-146a Mimic Encapsulated in Lipid Nanoparticles
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Kanika Suri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Cambridge, Massachusetts 02142, United States. Hauptthemen laut MEDLINE: MicroRNAs, Inflammatory Bowel Diseases, Nanoparticles, Lipids. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Takeda Development Center Americas.
Abstract (Originalsprache)
Dysregulated microRNAs (miRNAs) have significant potential as diagnostic tools for various chronic diseases; however, their therapeutic applications remain largely unexplored. Given their capacity to regulate multiple pathways, miRNAs are promising candidates for treating pleiotropic diseases, such as inflammatory bowel disease (IBD). In our study, we conducted a comprehensive review of the literature of miRNA-146 levels in the inflamed tissues of IBD patients and murine colitis models. Initially, we quantified the expression of miRNA-146a and miRNA-146b in the colons of mice using the dextran sodium sulfate (DSS)-inducedacute model of IBD. We selected miRNA-146a for further study due to its anti-inflammatory properties and potential relevance in IBD treatment. We hypothesized that a macrophage model of inflammation would be well-suited to studying the effects of this miRNA. Subsequently, we investigated the use of lipid nanoparticles (LNPs) for the targeted delivery of miRNA-146a to macrophages, which play a key role in IBD. Our results indicated that miRNA-146a levels increased in the DSS model and LNP-mediated delivery effectively downregulated genes associated with inflammation. These findings highlight the critical role of miRNA-146a in modulating IBD and suggest that LNP-based delivery could be a promising therapeutic strategy for managing inflammatory responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Takeda Development Center Americas, Cambridge, Massachusetts 02142, United States.
- Department of Bioengineering, College of Engineering, Northeastern University, Boston, Massachusetts 02120, United States.
- The Jackson Laboratory, Bar Harbor, Maine 04609, United States.
- Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
- Department of Chemical Engineering, College of Engineering, Northeastern University, Boston, Massachusetts 02115, United States.
ORCID-Profile: Mansoor M Amiji
Förderung
- NCI NIH HHS
- National Cancer Institute
- Takeda Development Center Americas
Zitieren
APA
Suri, K., Hosur, V., Panchakshari, R., & Amiji, M. M. (2025). A Multimodal Therapeutic Strategy for Inflammatory Bowel Disease Using MicroRNA-146a Mimic Encapsulated in Lipid Nanoparticles. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00014
Vancouver
Suri K, Hosur V, Panchakshari R, Amiji MM. A Multimodal Therapeutic Strategy for Inflammatory Bowel Disease Using MicroRNA-146a Mimic Encapsulated in Lipid Nanoparticles. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00014
BibTeX
@article{Suri2025,
author = {Suri, Kanika and Hosur, Vishnu and Panchakshari, Rohit and Amiji, Mansoor M},
title = {A Multimodal Therapeutic Strategy for Inflammatory Bowel Disease Using MicroRNA-146a Mimic Encapsulated in Lipid Nanoparticles},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00014}
}
EUVIMED